# Pharmacology and Obesity Treatment

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/pharmacology-and-obesity-treatment/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the pharmacological management of obesity, including the use of anti-obesity drugs, clinical trials evaluating their efficacy and safety, and the impact on weight loss. It covers a wide range of medications such as sibutramine, orlistat, and ephedra alkaloids, as well as their associated adverse events and lipase inhibitors. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12539 |
| Works | 210 |

## Topic papers all

Showing 15 of 210.

- [2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults](https://scholariq.org/papers/2014-evidence-based-guideline-for-the-management-of-high-blood-pressure-in/)
- [Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38](https://scholariq.org/papers/tight-blood-pressure-control-and-risk-of-macrovascular-and-microvascular/)
- [2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults](https://scholariq.org/papers/2013-aha-acc-tos-guideline-for-the-management-of-overweight-and-obesity-in/)
- [High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.](https://scholariq.org/papers/high-density-lipoprotein-cholesterol-and-cardiovascular-disease-four-prospective/)
- [2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults](https://scholariq.org/papers/2013-aha-acc-tos-guideline-for-the-management-of-overweight-and-obesity-in-2/)
- [A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management](https://scholariq.org/papers/a-randomized-controlled-trial-of-3-0-mg-of-liraglutide-in-weight-management/)
- [Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis](https://scholariq.org/papers/antipsychotic-induced-weight-gain-a-comprehensive-research-synthesis/)
- [Valvular Heart Disease Associated with Fenfluramine–Phentermine](https://scholariq.org/papers/valvular-heart-disease-associated-with-fenfluramine-phentermine/)
- [Weight-Loss Outcomes: A Systematic Review and Meta-Analysis of Weight-Loss Clinical Trials with a Minimum 1-Year Follow-Up](https://scholariq.org/papers/weight-loss-outcomes-a-systematic-review-and-meta-analysis-of-weight-loss/)
- [2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes](https://scholariq.org/papers/2023-esc-guidelines-for-the-management-of-cardiovascular-disease-in-patients/)
- [Obesity in adults: a clinical practice guideline](https://scholariq.org/papers/obesity-in-adults-a-clinical-practice-guideline/)
- [Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39](https://scholariq.org/papers/efficacy-of-atenolol-and-captopril-in-reducing-risk-of-macrovascular-and/)
- [Diabetes, Hypertension, and Cardiovascular Disease](https://scholariq.org/papers/diabetes-hypertension-and-cardiovascular-disease/)
- [Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline](https://scholariq.org/papers/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice/)
- [KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease](https://scholariq.org/papers/kdigo-2022-clinical-practice-guideline-for-diabetes-management-in-chronic-kidney/)

## Topic primary papers

Showing 15 of 48.

- [Valvular Heart Disease Associated with Fenfluramine–Phentermine](https://scholariq.org/papers/valvular-heart-disease-associated-with-fenfluramine-phentermine/)
- [Obesity in adults: a clinical practice guideline](https://scholariq.org/papers/obesity-in-adults-a-clinical-practice-guideline/)
- [Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline](https://scholariq.org/papers/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice/)
- [Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/effects-of-low-dose-controlled-release-phentermine-plus-topiramate-combination/)
- [Management of obesity](https://scholariq.org/papers/management-of-obesity/)
- [Meta-Analysis: Pharmacologic Treatment of Obesity](https://scholariq.org/papers/meta-analysis-pharmacologic-treatment-of-obesity/)
- [Obesity prevalence from a European perspective: a systematic review](https://scholariq.org/papers/obesity-prevalence-from-a-european-perspective-a-systematic-review/)
- [Quality of life and obesity](https://scholariq.org/papers/quality-of-life-and-obesity/)
- [Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study](https://scholariq.org/papers/role-of-orlistat-in-the-treatment-of-obese-patients-with-type-2-diabetes-a-1/)
- [2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death](https://scholariq.org/papers/2-4-dinitrophenol-dnp-a-weight-loss-agent-with-significant-acute-toxicity-and/)
- [Obesity as a disease: no lightweight matter](https://scholariq.org/papers/obesity-as-a-disease-no-lightweight-matter/)
- [Long-term weight loss maintenance for obesity: a multidisciplinary approach](https://scholariq.org/papers/long-term-weight-loss-maintenance-for-obesity-a-multidisciplinary-approach/)
- [Retracted: Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials](https://scholariq.org/papers/retracted-pharmacotherapy-for-adults-with-overweight-and-obesity-a-systematic/)
- [Pharmacotherapy of obesity: Available medications and drugs under investigation](https://scholariq.org/papers/pharmacotherapy-of-obesity-available-medications-and-drugs-under-investigation/)
- [Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date](https://scholariq.org/papers/naltrexone-sustained-release-bupropion-sustained-release-for-the-management-of/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.